肺癌DC融合细胞诱导的抗肿瘤免疫应答

目的 研究肺癌DC融合细胞FLD－A11体内外诱导免疫应答的能力,方法 用MTT法测定FLD－A11细胞诱导淋巴细胞增殖的能力;ELISA法检测其诱导淋巴细胞分泌IL－2的水平;LDH释放法测定FLD－A11细胞免疫后小鼠脾淋巴细胞的特异性CTL活性。结果 FLD－A11有有效刺激淋巴细胞的增殖反应（SC：RC＝1：50时,SI＝2.38）,诱导淋巴细胞分泌IL－2。FLD－A11细胞免疫后,小鼠的胸腺和脾脏重量均高于对照组（P＜0.05）,脾淋巴细胞对Lewis肺癌细胞的杀伤活性显著高于对照组。结论 FLD－A11细胞具有诱导初次抗肿瘤免疫应答的能力,不仅能在体外诱导淋巴细胞的增殖和IL－2的分泌,而且体内免疫接种也能引起小鼠免疫器官的增生反应,产生针对Lewis肺癌的特异性CTL杀伤作用。     

结核分枝杆菌MPT64重组母牛分枝杆菌免疫学特性

目的:研究结核分枝杆菌MPT64重组母牛分枝杆菌疫苗免疫学特性.方法:用分泌表达MPT64的重组母牛分枝杆菌疫苗免疫BALB/c小鼠,ELISA法检测免疫小鼠的特异性抗体滴度和抗体亚类.分离免疫小鼠脾淋巴细胞,检测淋巴细胞增殖、IFN-γ和IL-12产生水平、CD4+细胞和CD8+细胞数、脾淋巴细胞特异性CTL杀伤效应.毒株攻击后对脾脏细菌负荷计数.结果:MPT64重组母牛分枝杆菌疫苗免疫可诱导小鼠高水平的体液免疫应答,免疫小鼠脾淋巴增殖明显,IFN-γ和IL-12含量增加,CD4+和CD8+细胞百分比明显增加,CTL杀伤效应明显,对MTB H37Rv攻击后有一定的保护作用.结论:MPT64重组母牛分枝杆菌疫苗可诱导小鼠有效的体液和细胞免疫应答,有可能作为新型TB疫苗候选.     

探讨BCG初次免疫结核杆菌DNA疫苗加强免疫方案的效应

目的:探讨BCG初次免疫(BCG-prime),结核杆菌共表达DNA疫苗加强免疫(DNA疫苗-boost)的策略对小鼠的免疫效果。方法:将BCG及结核杆菌重组DNA疫苗依次免疫小鼠,通过检测CTL和NK细胞的杀伤活性和特异性淋巴细胞增殖,以及小鼠血清抗体及细胞因子的水平,观测BCG-prime、共表达结核杆菌Ag85A/GM-CSFDNA疫苗boost策略对小鼠的免疫效果。结果:采用prime-boost免疫策略组的小鼠CTL的杀伤活性明显增强、特异性淋巴细胞明显增殖、IFN-γ的水平明显增高,NK细胞杀伤活性与对照组相比也有一定提高,但未超过BCG单独免疫效果。免疫小鼠血清特异性抗体的滴度超过单独DNA疫苗免疫组。结论:在采用BCG-prime-结核杆菌DNA疫苗boost免疫策略后,能增强对小鼠的免疫效应,尤其是Th1型细胞免疫反应增强明显,为进一步在动物体内进行保护性效应试验的研究提供了实验依据。     

淫羊藿苷(ICA)对化疗后免疫抑制小鼠的免疫促进作用

目的:通过观察淫羊藿苷(ICA)对化疗药环磷酰胺(Cy)所致免疫抑制小鼠免疫功能的影响,探讨ICA促进免疫功能的作用及机理.方法:除正常组小鼠外,所有小鼠经腹腔注射Cy(300 mg/kg);第二天开始给予实验组小鼠灌胃不同剂量的ICA[150、80、40 mg/(kg·d)],阳性对照组小鼠尾静脉注射参芪扶正注射液(1 ml/d),模型组给予等量生理盐水,连续干预10天.所有小鼠均于末次给药12小时后处死,计算胸腺指数(TI)和脾指数(SI),光镜下计数外周血和脾淋巴细胞数量.MTT法检测小鼠脾淋巴细胞增殖反应.ELISA法检测TNF-α的含量.乳酸脱氢酶实验(LDH)检测小鼠脾脏NK和CTL细胞的活性.流式细胞术(FACS)检测脾淋巴细胞中NKT和CD3+T细胞的比例.结果:模型组小鼠以上各项免疫指标均有所下降.ICA处理组小鼠脾脏指数和胸腺指数均升高(P<0.01),脾淋巴细胞数量显著增加(P<0.01),但未达到正常对照组水平;ICA明显提高小鼠脾淋巴细胞的增殖反应,促进了小鼠脾NK和CTL细胞对肿瘤细胞的杀伤活性(P<0.01),提高了小鼠脾细胞TNF-α的产生(P<0.01).ICA处理组小鼠脾细胞中CD3+T、NKT细胞比例明显增加(P<0.01).结论:ICA能促进小鼠免疫功能,具有逆转化疗后小鼠免疫抑制状态的作用.     

四氧嘧啶糖尿病小鼠免疫状态及胰岛素免疫调节作用的研究

本文以四氧嘧啶糖尿病小鼠为模型,探讨了糖尿病小鼠在高血糖低胰岛素状态下对免疫器官、自然杀伤活性细胞、脾淋巴细胞增殖及IL-2产生的影响。结果表明,高血糖低胰岛素状态可致小鼠脾脏及胸腺明显萎缩,脾细胞总数减少(均P<0.01)。体内YAC-1细胞清除率降低,淋巴细胞对ConA的增殖反应及IL-2产生能力减弱。体外给予胰岛素可使病鼠淋巴细胞对ConA的增殖反应显著升高,IL-2合成增多,表明胰岛素具有重要的免疫调节作用。     

共表达HIV-1 gp120与IFN-α重组鸡痘病毒诱导特异性CTL的初步研究

目的:探讨共表达HIV -1gp12 0与IFN- α重组鸡痘病毒诱导小鼠产生特异性的CTL杀伤活性。方法:将重组鸡痘病毒经肌肉注射免疫BALB c小鼠后,制备小鼠脾淋巴细胞悬液。以免疫小鼠的脾淋巴细胞为效应细胞,以表达HIV- 1结构蛋白的P815细胞为靶细胞,用乳酸脱氢酶释放法测定免疫小鼠脾特异性CTL杀伤活性。结果:重组病毒可有效地诱导特异性CTL的产生,且重组病毒免疫组小鼠脾特异性CTL对靶细胞的杀伤活性显著高于FPV对照组(P <0 .0 1)和PBS对照组(P <0. 0 1)。结论:共表达HIV- 1gp12 0和IFN -α的重组鸡痘病毒可激发强烈的细胞免疫,可作为我国HIV- 1疫苗候选株。     

实验性自身免疫性甲状腺炎小鼠细胞免疫状态研究

作者检测了实验性自身免疫性甲状腺炎(EAT)小鼠的细胞免疫状态,结果表明:EAT小鼠脾细胞Thy-1.2和Lyt-2阳性T细胞数显著下降并伴随L3T4/Lyt-2阳性T细胞数比值升高;甲状腺球蛋白刺激的淋巴细胞增殖明显增强,但NK细胞活性无显著变化;脾细胞产生TNF和IL-1的水平明显高于正常小鼠。提示T细胞免疫功能紊乱和细胞因子的大量释放可能是引起此病的重要因素。     

表达CRT-E2融合蛋白肿瘤疫苗诱导特异性抗肿瘤免疫应答

目的:探讨表达钙网蛋白(Calreticulin,CRT)和HPV E2融合蛋白的肿瘤疫苗在小鼠体内诱导的抗肿瘤免疫应答.方法:转染重组质粒得到高表达CRT、E2和CRT-E2融合蛋白的肿瘤细胞,作为肿瘤疫苗隔周两次腹腔注射免疫小鼠,17天后观察成瘤率,检测NK细胞杀伤活性、特异性T细胞增殖能力、CIL活性以及睥淋巴细胞分泌IFN-γ水平,并观察荷瘤小鼠生存期.结果:高表达CRT-E2融合蛋白肿瘤疫苗免疫小鼠后,其成瘤率明显低于其他实验组,NK细胞杀伤活性、特异性T细胞增殖能力、CTL活性和脾淋巴细胞分泌IFN-γ水平均显著高于其它实验组(P＜0.01),生存期也明显延长(P＜0.01).结论:小鼠体内实验显示,表达CRT-E2融合蛋白肿瘤疫苗能够诱导特异性CD8+T细胞免疫应答和NK细胞活性,显著抑制了肿瘤生长.     

IL-2和GM-CSF表达质粒对pcDNA3/MDC-VP1 DNA疫苗作用的比较

目的:比较IL-2与GM-CSF两种细胞因子对pcDNA3/MDC-VP1 DNA疫苗免疫的免疫增强效果.方法:4～6周龄雄性BALB/c小鼠随机分成pcDNA3组、pcDNA3/MDC-VP1组、pcDNA3/MDC-VP1与pcDNA3/hIL-2混合注射组、pcDNA3/MDC-VP1与pcDNA3/mGM-CSF混合注射组,每组10只.每3周接种1次,共3次.每次接种后的第20天眼眶采血,用微量中和试验(固定病毒-稀释血清法)检测血清中和抗体效价.第3次免疫后3周,每组取3只小鼠脾脏制备淋巴细胞悬液,检测淋巴细胞增殖活性与特异性细胞毒性T淋巴细胞(CTL)杀伤活性.结果:pcDNA3/MDC-VP1+pcDNA3/mGM-CSF组的血清中和抗体滴度明显提高,小鼠脾脏淋巴细胞增殖活性和特异性CTL杀伤活性均有增强.结论:GM-CSF作为本疫苗分子佐剂能诱导小鼠产生较强的体液和细胞免疫,免疫效果优于IL-2.     

Flt3L及CCL5对prime/boost免疫策略中抗原特异性免疫应答的增强及抗肿瘤作用

目的:研究Flt3L与CCL5作为联合佐剂在prime/boost免疫策略中对HBc抗原特异性免疫应答的增强及抗肿瘤作用.方法:将两种细胞因子质粒与携带HBc抗原的DNA疫苗经肌内注射法共免疫小鼠, 免疫3次后再用原核表达的HBc颗粒蛋白或HBc DNA疫苗加强, 观察对稳定表达HBcAg 的小鼠黑色素瘤细胞(B16-HBc)的生长抑制作用;并分别采用MTT法检测荷瘤小鼠脾淋巴细胞增殖、流式细胞术检测脾CD8 T淋巴细胞中IFN-γ表达、ELISA法检测脾淋巴细胞培养上清IL-2、IL-4含量及乳酸脱氢酶(LDH)释放法检测特异性CTL杀伤活性.结果:与对照组相比, 佐剂联合DNA疫苗免疫经蛋白加强组(DDP/Adj)显著抑制肿瘤生长;佐剂联合DNA疫苗免疫组(DDD/Adj)及DDP/Adj组均可促进特异性淋巴细胞增殖反应(P＜0.05), 且DDP/Adj 高于DDD/Adj组(P＜0.05);DDD/Adj 及DDP/Adj组小鼠脾脏CD8 T淋巴细胞中IFN-γ表达、IL-2 表达水平及CTL杀靶活性均高于对照组(P＜0.01或P＜0.05), IL-4 表达水平在各组无显著区别(P＞0.05).结论:在prime/boost免疫策略中, 采用Flt3L与CCL5两种细胞因子联合应用可显著促进荷瘤小鼠产生抗原特异性免疫应答及抗肿瘤作用.     

小鼠对HIV-2 gp105核酸疫苗免疫应答的研究

目的: 探讨HIV- 2gp105基因核酸疫苗在小鼠体内的免疫应答, 为开发HIV- 2核酸疫苗提供实验依据。方法:将HIV- 2外膜蛋白 (gp105 )基因插入真核表达质粒载体pVAX1中, 构建pVAX1 gp105重组表达质粒。将其肌注免疫BALB/c小鼠, 用ELISA法检测小鼠血清抗HIV -2抗体, 用流式细胞仪测定CD4 、CD8 T细胞亚群数, 以乳酸脱氢霉释放法检测脾特异性CTL的杀伤活性。结果: 重组质粒pVAX1 -gp105免疫组小鼠的血清抗体滴度、脾T细胞亚群的数量及特异性CTL的杀伤活性, 均明显高于对照组, 分别为P<0. 01, P<0. 05和P<0. 01。结论: HIV -2gp105核酸疫苗能诱导小鼠产生特异性细胞和体液免疫。     

OAZI-1 蛋白复合物在小鼠体内诱导特异性抗肿瘤效应的研究

目的:在实验动物的水平上分析来源于肿瘤细胞的鸟氨酸脱羧酶抗酶抑制因子-1(Ornithine decarboxylaseantizyme inhibitor-1,OAZI-1) 蛋白复合物能否在小鼠体内诱导特异性抗肿瘤效应。方法:用包被有OAZI-1 抗体的免疫磁珠从B16-F1 小鼠黑色素瘤细胞中分离OAZI-1 蛋白复合物,用此复合物免疫小鼠后, 再在小鼠皮下接种B16-F1 活细胞,然后观察接种瘤在小鼠体内的成瘤及生长状况。ELISA 法用于检测免疫小鼠血清中IFN-γ含量。乳酸脱氢酶释放实验(LDH)检测免疫小鼠脾脏淋巴细胞对B16-F1 细胞的杀伤效应。上述动物实验用原核表达纯化的OAZI-1 蛋白和PBS 免疫的小鼠作为对照。结果:与对照小鼠相比,接种OAZI-1 蛋白复合物的小鼠脾淋巴细胞(效应细胞)对B16-F1 黑素瘤细胞(靶细胞)具有更强的杀伤能力。在三种不同的效：靶比下(10 ：1、50 ：1、100 ：1),该组小鼠脾淋巴细胞对靶细胞的杀伤活性分别为46.2%、59.5% 和92.5%,显著性高于接种纯化OAZI-1 蛋白组(36.1%、26.8% 和45.9%)和接种PBS 组(24.6%、24.0% 和27.2%)小鼠脾淋巴细胞。此外,接种OAZI-1 蛋白复合物的小鼠血清中抗肿瘤细胞因子IFN-γ含量(538.3 pg/ ml)也显著性高于接种纯化OAZI-1 蛋白组(256.2 pg/ ml)和接种PBS 组(131.0 pg/ ml)小鼠。上述方法免疫的小鼠在皮下再接种B16-F1 活细胞后,免疫OAZI-1 蛋白复合物组小鼠成瘤率为40%,而PBS 组和纯化OAZI-1 蛋白组小鼠成瘤率为100%,且接种瘤在OAZI-1 蛋白复合物免疫小鼠体内生长更为缓慢。结论:从B16-F1 肿瘤细胞中分离的OAZI-1 蛋白复合物中可能含有肿瘤抗原,用此复合物接种小鼠能在实验动物体内诱导抗肿瘤免疫杀伤活性。     

Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis

Oral antigen is an attractive approach for the treatment of autoimmune and inflammatory diseases. Establishment of immune markers and methods in evaluating the effects of antigen-specific cellular and humoral immune responses will help the application of oral tolerance in the treatment of human diseases. The present article observed the effects of chicken collagen II (CII), the recombinant polymerized human collagen II 250-270 (rhCII 250-270) peptide and synthesized human CII 250-270 (syCII 250-270) peptide on the induction of antigen-specific autoimmune response in rheumatoid arthritis (RA) peripheral blood mononuclear cells (PBMC) and on the specific cellular and humoral immune response in collagen-induced arthritis (CIA) and mice fed with CII (250-270) prior to immunization with CII. In the study, proliferation, activation and intracellular cytokine production of antigen-specific T lymphocytes were simultaneously analyzed by bromodeoxyuridine (BrdU) incorporation and flow cytometry at the single-cell level. The antigen-specific antibody and antibody-forming cells were detected by ELISA and ELISPOT, respectively. CII (250-270) was found to have stimulated the response of specific lymphocytes in PBMC from RA patients, including the increase expression of surface activation antigen marker CD69 and CD25, and DNA synthesis. Mice, fed with CII (250-270) before CII immunization, had significantly lower arthritic scores than the mice immunized with CII alone, and the body weight of the former increased during the study period. Furthermore, the specific T cell activity, proliferation and secretion of interferon (IFN)-gamma in spleen cells were actively suppressed in CII (250-270)-fed mice, and the serum anti-CII, anti-CII (250-270) antibody activities and the frequency of specific antibody-forming spleen cells were significantly lower in CII (250-270)-fed mice than in mice immunized with CII alone. These observations suggest that oral administration of CII (250-270) can suppress the cellular and humoral immune response in collagen-induced arthritis, and the simultaneous analysis of antigen-specific cellular and humoral immune responses at single-cell level will help the understanding of the oral tolerance mechanisms in CIA and the development of innovative therapeutic intervention for RA.     

mIL-21基因转染的Sp2/0瘤苗细胞的抗肿瘤机制探讨

目的:探讨小鼠IL-21瘤苗-Sp2/0-mIL-21抗肿瘤效应的机制。方法:用流式细胞术检测Sp2/0-mIL-2瘤苗细胞表面MHC-Ⅰ类分子及CD80分子的表达。以瘤苗细胞接种BALB/c小鼠,以CFSE,7-AAD标记,用流式细胞术检测NK细胞、CTL的细胞毒活性。观察肿瘤组织中淋巴细胞的浸润。用RT-PCR检测肿瘤组织中CXC家族趋化因子I-TAC的表达。结果:与对照组相比,瘤苗细胞膜表面MHC-Ⅰ类分子的表达明显上调。瘤苗接种组小鼠NK细胞、CTL的细胞毒活性明显增强。病理分析发现,肿瘤组织中有较多的淋巴细胞浸润并检测到干扰素诱导的T细胞α趋化因子(I-TAC)的表达上调。结论:肿瘤细胞瘤苗Sp2/0-mIL21可增强小鼠的细胞免疫作用,其抗肿瘤机制可能与T细胞的增殖、活化,促进NK细胞的分化成熟,淋巴细胞向肿瘤组织浸润,以及增强NK细胞和CTL的细胞毒活性有关。     

IL-18和HIV-1 gag-gp120嵌合基因DNA疫苗联合免疫小鼠的免疫应答

目的 :探讨IL 18和HIV 1gag gp12 0嵌合基因的DNA疫苗联合免疫小鼠的免疫应答。方法 :构建含IL 18的真核表达质粒pVAXIL18,将他与表达HIV 1gag gp12 0嵌合基因的核酸疫苗质粒pVAXGE共同肌注免疫BALB/c小鼠 ,检测免疫小鼠脾特异性CTL杀伤活性和血清抗体滴度。结果 :联合免疫组小鼠脾特异性CTL杀伤活性和血清抗体水平均显著高于单独免疫组 (P <0 .0 5 ) ,空白质粒对照组 (P <0 .0 1)和PBS对照组 (P <0 .0 1)。结论 :IL 18和HIV 1gag gp12 0嵌合基因的DNA疫苗联合免疫可诱导小鼠产生特异性细胞和体液免疫 ,且IL 18发挥了免疫佐剂的作用。     

The Antinociceptive Effect of Dexmedetomidine Modulates Spleen Cell Immunity in Mice

Background: Pain plays roles in both the nervous system and immune system. Changes in the neuroendocrine pathway under pain conditions give rise to sympathetic outflow with increased plasma catecholamines and activate immune reactions. Dexmedetomidine exerts sedative, analgesic, and anesthetic-sparing effects and is known to diminish pro-inflammatory processes by central sympatholytic effects. To investigate the influence of the analgesic effect of dexmedetomidine on immunomodulation under pain conditions, splenic natural killer (NK) tumoricidal cytotoxic activity, proliferative ability of T lymphocytes, and cytokine changes were assessed.Methods: After evaluation of the analgesic efficacy of dexmedetomidine in C57BL mice that were subjected to formalin-induced pain, dexmedetomidine (30 µg/kg) or saline was injected intraperitoneally (ip) 30 min before formalin (20 µL of 2% formalin in 0.9% saline) injection. NK cell activity against NK-sensitive YAC-1 lymphoma cells was evaluated by the percentage of specific lactate dehydrogenase (LDH) release. Various numbers of effector cells (NK cells) were added to the wells of a microtiter plate containing 2 × 10⁴ target YAC-1 cells in 100 μL, to achieve final effector-to-target cell ratios of 80:1, 40:1, and 20:1. The level of lymphocyte proliferation in response to phytohemagglutinin (PHA) was detected by bromodeoxyuridine (BrdU) incorporation assay. TNF-α, IL-1β, and IL-10 levels were determined in blood samples and supernatants of splenocyte preparations.Results: IP administration of dexmedetomidine significantly decreased the time of licking and biting during the first and second phases of the formalin test (p <0.001). Formalin-induced pain led to higher activity of NK cells than in sham-treated mice (p <0.05), but NK activity was not increased significantly by ip dexmedetomidine treatment. Formalin-induced pain significantly increased splenic lymphocyte proliferation (p <0.05), but dexmedetomidine did not alter this response. There was a significant increase in plasma TNF-α (p = 0.048) and IL-6 (p = 0.014) levels after formalin-induced pain. However, the differences between the responses after ip dexmedetomidine did not change significantly.Conclusions: Dexmedetomidine showed antinociceptive effect on both of acute pain phase 1 and hyperalgesic phase 2 of formalin pain model. Formalin-induced pain alters cellular immunity of spleen in mice. Dexmedetomidine attenuates the activation of NK cells under pain condition, but neither the proliferative response of the splenic lymphocytes nor the cytokine production was affected by dexmedetomidine.     

Effect of acute pain on splenic NK cell activity, lymphocyte proliferation and cytokine production activities

Various types of physical and physiological stress in animals have been shown to affect their humoral and cell-mediated immune responses. The present study was designed to investigate the possible influence of acute pain on the immune system. BALB/c mice were exposed to an increasing number of heat shocks using a Tail Flick apparatus; an equal number of control mice received no shock treatments. After each of the regimens was completed, the spleen of each mouse was recovered and various cell populations isolated to assess: the proliferative response to phytohemagglutinin by lymphocytes; cytotoxic activities of natural killer (NK) cells; and, the production of select important cytokines by splenic lymphocytes. The results indicated that NK cell activity and proliferation of lymphocytes were significantly (p < 0.001) increased due to the shock regimens after only a single day's rounds of stimulation (i.e., 3 rounds of approximately 12 equally time-spaced shocks/hr with 30-45 min gap between rounds). After 2 and 3 days' rounds of stimulations, no significant changes were detected in the proliferative response of isolated lymphocytes; conversely, the activity of NK cells remained significantly elevated compared to the controls hosts' cells, even on the second day of stimulation but not on the third. Regarding effects on cytokines, no significant changes were detected in the amount of Interferon-gamma (IFNgamma) and Interlukin-10 (IL-10) produced by lymphocytes obtained from the spleens of any of the shocked mice. These results could suggest that certain acute stressors might actually strengthen a host's immunological reactivity and, possibly, result in an enhanced capacity to resist pathogens that might infect the body.     

Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles

Recombinant human papillomavirus (HPV) type 16 L1 virus-like particles (VLPs) expressed in the baculovirus system were used to investigate the cellular immune response to human papillomavirus type 16. The cell-mediated immune response was evaluated through immunization of mice with HPV 16 L1 virus-like particles using a lymphoproliferation assay and cytokine production and cytometric analysis of lymphocyte subsets. A significant proliferative response was observed which was associated with secretion of both interferon-γ and interleukin-2. FACS analysis of splenic lymphocytes revealed that CD8⁺T-cells were increased in the immunized mice. These results demonstrate that HPV 16 L1 VLPs induce a T-cell response characterized by a Th1 profile and confirm that the HPV 16 VLP is a reasonable candidate for vaccine development.     

乙型肝炎病毒多表位抗原DNA疫苗的免疫原性

目的 :探讨HBV复合多表位DNA疫苗诱导体液及细胞免疫的可行性。方法 :将HBV多表位抗原基因BPT克隆到真核表达载体pcDNA3.1中 ,构建重组真核表达载体pcDNA3.1/BPT。将其通过肌肉注射免疫BALB/c小鼠 ,用间接免疫ELISA法、CTL杀伤功能检测和淋巴细胞增殖试验 ,检测特异性体液免疫和细胞免疫的水平 ,并观察其对免疫小鼠的毒副作用。结果 :用重组质粒pcDNA3.1/BPT免疫BALB/c小鼠后 ,在效靶比为 10 0∶1时 ,可诱导显著地特异性CTL应答 (P <0 .0 5 )。ELISA检测免疫小鼠血清特异性IgG的水平明显升高 (P <0 .0 5 )。在BPT基因原核表达蛋白的刺激下 ,免疫小鼠脾淋巴细胞增殖显著 (P <0 .0 5 )。RT PCR分析表明 ,IL 12mRNA的水平亦明显升高。结论 :HBV多表位基因疫苗可诱发特异性免疫应答 ,为预防、治疗性HBV疫苗的研制提供了一定的实验依据